Neel is a postdoc fellow in the Pratx lab at Stanford University. He is currently working on the role of radiotherapy in cancer cell death and the various mechanism involved in radio-induced cell death. Neel comes from a very small town in Odisha, India (Athgarh) and had schooling in his hometown. He had a keen interest in animal biology and started his B.S in Zoology at Gopabandhu Science College, Athgarh. Later he did his M.S in Zoology from Sambalpur University, Odisha, India. He carried out his doctoral studies at the Indian Institute of Technology Roorkee in the lab of Prof. Partha Roy. His main study was on the anti-cancer activity of various natural-based products and their mechanism of action. Neel is a trained cell and molecular biologist. His research interest includes- Cancer cell death mechanisms and developing therapeutics for cancer stem cells and metastasis.
Honors & Awards
Best Poster Award, NATIONAL BIOMEDICAL RESEARCH COMPETITION -2018 (2018)
University Gold Medal for securing 1st rank in university in M.S (Zoology) examination, Sambalpur University, India (2014)
University topper in Utkal University in B.S (Zoology) examination., Utkal University, India (2007)
Doctor of Philosophy, Indian Institute of Technology, Roorkee (2021)
Master of Science, Sambalpur University (2015)
Bachelor of Science, Utkal University (2008)
Ph.D., INDIAN INSTITUTE OF TECNOLOGY ROORKEE, CANCER BIOLOGY (2022)
M.S, SAMBALPUR UNIVERSITY, INDIA, ZOOLOGY (2014)
B.S, UTKAL UNIVERSITY,INDIA, ZOOLOGY (2007)
Guillem Pratx, Postdoctoral Faculty Sponsor
Efficient and multiplexed tracking of single cells using whole-body PET/CT.
bioRxiv : the preprint server for biology
In vivo molecular imaging tools are crucially important for elucidating how cells move through complex biological systems, however, achieving single-cell sensitivity over the entire body remains challenging. Here, we report a highly sensitive and multiplexed approach for tracking upwards of 20 single cells simultaneously in the same subject using positron emission tomography (PET). The method relies on a new tracking algorithm (PEPT-EM) to push the cellular detection threshold to below 4 Bq/cell, and a streamlined workflow to reliably label single cells with over 50 Bq/cell of 18F-fluorodeoxyglucose (FDG). To demonstrate the potential of method, we tracked the fate of over 70 melanoma cells after intracardiac injection and found they primarily arrested in the small capillaries of the pulmonary, musculoskeletal, and digestive organ systems. This study bolsters the evolving potential of PET in offering unmatched insights into the earliest phases of cell trafficking in physiological and pathological processes and in cell-based therapies.
View details for DOI 10.1101/2023.08.23.554536
View details for PubMedID 37662335
View details for PubMedCentralID PMC10473747
Preclinical evaluation of 89Zr-Panitumumab for biology-guided radiotherapy.
International journal of radiation oncology, biology, physics
Biology-guided radiotherapy (BgRT) uses real-time line-of-response data from on-board PET detectors to guide beamlet delivery during therapeutic radiation. The current workflow requires 18F-fluorodeoxyglucose (FDG) administration daily prior to each treatment fraction. However, there are advantages to reducing the number of tracer injections by using a PET tracer with a longer decay time. In this context, we investigated 89Zr-Panitumumab (89Zr-Pan), an antibody PET tracer with a half-life of 78 hours that can be imaged for up to 9 days using PET.The BgRT workflow was evaluated pre-clinically in mouse colorectal cancer xenografts (HCT116) using small-animal PET/CT for imaging, and image-guided kilovoltage conformal irradiation for therapy. Mice (n=5 per group) received 7 MBq of 89Zr-Pan as a single dose 2 weeks after tumor induction, with or without fractionated radiation therapy (RT; 6×6.6 Gy) to the tumor region. The mice were imaged longitudinally to assess the kinetics of the tracer over 9 days. PET images were then analyzed to determine the stability of the PET signal in irradiated tumors over time.Mice in the treatment group experienced complete tumor regression, whereas those in the control group were sacrificed due to tumor burden. PET imaging of 89Zr-Pan showed well-delineated tumors with minimal background in both groups. On day 9 post-injection, tumor uptake of 89Zr-Pan was 7.2 ± 1.7 in the control group vs 5.2 ± 0.5 in the treatment group (mean %ID/g ± SD; P = 0.07), both significantly higher than FDG uptake (1.1 ± 0.5 %ID/g) 1 hour post injection. To assess BgRT feasibility, the clinical eligibility criteria was computed using human-equivalent uptake values that were extrapolated from preclinical PET data. Based on this semiquantitative analysis, BgRT may be feasible for 5 consecutive days following a single 740 MBq injection of 89Zr-Pan.This study indicates the potential of long-lived antibody-based PET tracers for guiding clinical BgRT.
View details for DOI 10.1016/j.ijrobp.2023.01.007
View details for PubMedID 36669541
Real-time optical oximetry during FLASH radiotherapy using a phosphorescent nanoprobe.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
The rapid depletion of oxygen during irradiation at ultra-high dose rate calls for tissue oximeters capable of high temporal resolution. This study demonstrates a water-soluble phosphorescent nanoprobe and fiber-coupled instrument, which together are used to measure the kinetics of oxygen depletion at 200 Hz during irradiation of in vitro solutions.
View details for DOI 10.1016/j.radonc.2022.08.011
View details for PubMedID 35964762